RYR2 and Arrhythmia: Arrhythmias induced by silmitasertib (a casein kinase 2 inhibitor) and sunitinib have been reported to result from their effects on RyR2 and increased storage overload-induced Ca2+ release (Figure 1) (Chakraborty et al., 2019).